Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

ITP-Immune Thrombocytopenic Purpura (Archived)

In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

ITP-Immune Thrombocytopenic Purpura (Archived)

Angel A. Justiz Vaillant et al.
Free Books & Documents

Excerpt

Immune thrombocytopenic purpura (ITP) is an autoimmune disease characterized by a low platelet count, purpura, and hemorrhagic episodes caused by antiplatelet autoantibodies. The diagnosis is typically made by excluding the known causes of thrombocytopenia. IgG autoantibodies sensitize the circulating platelets. It leads to the accelerated removal of these cells by antigen-presenting cells (macrophages) of the spleen and sometimes the liver or other components of the monocyte-macrophage system. The bone marrow compensates for platelet destruction by increasing platelet production. ITP most often occurs in healthy children and young adults within a few weeks following a viral infection.

ITP is usually manageable with immunosuppressive therapy. An identical form of autoimmune thrombocytopenia can also be associated with chronic lymphocytic leukemia, lymphomas, SLE, infectious mononucleosis, and other bacterial and viral infections. Certain drugs can also cause immune thrombocytopenia indistinguishable from ITP. Most children have spontaneous remission within a few weeks or months, and splenectomy is rarely needed. However, young adults rarely have spontaneous remissions necessitating splenectomy within the first few months after diagnosis.

The International Working Group on ITP defines ITP according to the following clinical phases. These are as follows:

  1. Newly diagnosed ITP is in the first three months post-diagnosis.

  2. Persistent ITP is for 3-12 months.

  3. Chronic ITP is for > 12 months.

  4. Refractory ITP is the failure of splenectomy.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Angel Justiz Vaillant declares no relevant financial relationships with ineligible companies.

Disclosure: Nagendra Gupta declares no relevant financial relationships with ineligible companies.

References

    1. Matzdorff A, Wörmann B. [Diagnosis and Therapy of Immune thrombocytopenia]. Dtsch Med Wochenschr. 2018 Aug;143(15):1076-1081. - PubMed
    1. Swinkels M, Rijkers M, Voorberg J, Vidarsson G, Leebeek FWG, Jansen AJG. Emerging Concepts in Immune Thrombocytopenia. Front Immunol. 2018;9:880. - PMC - PubMed
    1. Zitek T, Weber L, Pinzon D, Warren N. Assessment and Management of Immune Thrombocytopenia (ITP) in the Emergency Department: Current Perspectives. Open Access Emerg Med. 2022;14:25-34. - PMC - PubMed
    1. Karakurt N, Uslu İ, Albayrak C, Tomak L, Ozyazici E, Albayrak D, Aygun C. Neonates born to mothers with immune thrombocytopenia: 11 years experience of a single academic center. Blood Coagul Fibrinolysis. 2018 Sep;29(6):546-550. - PubMed
    1. Provan D, Semple JW. Recent advances in the mechanisms and treatment of immune thrombocytopenia. EBioMedicine. 2022 Feb;76:103820. - PMC - PubMed

Publication types

LinkOut - more resources